Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer
- 21 October 2011
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cancer and Metastasis Reviews
- Vol. 30 (3-4), 507-523
- https://doi.org/10.1007/s10555-011-9311-2
Abstract
Unresolved inflammation, due to insufficient production of proresolving anti-inflammatory lipid mediators, can lead to an increased risk of tumorigenesis and tumor cell invasiveness. Various bioactive lipids, particularly those formed by cyclooxygenase (COX) and lipoxygenase (LOX) enzymes, have been well established as therapeutic targets for many epithelial cancers. Emerging studies suggest that there is a role for anti-inflammatory bioactive lipids and their mediators during the resolution phase of inflammation. These proresolving bioactive lipids, including lipoxins (LXs) and resolvins (RVs), have potent anti-inflammatory and anti-carcinogenic properties. The molecular signaling pathways controlling generation and degradation of the proresolving mediators LXs and RVs are now being elucidated, and the component molecules may serve as new targets for regulation of inflammation and inflammation-associated cancers like colon and pancreatic cancers. This review will highlight the recent advances in our understanding of how these bioactive lipids and proresolving mediators may function with various immune cells and cytokines in inhibiting tumor cell proliferation and progression and invasiveness of colon and pancreatic cancers.Keywords
This publication has 117 references indexed in Scilit:
- Resolvin E1-induced intestinal alkaline phosphatase promotes resolution of inflammation through LPS detoxificationProceedings of the National Academy of Sciences, 2010
- Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodium–induced colitisInflammatory Bowel Diseases, 2010
- Epidemiology of pancreatic cancer: an overviewNature Reviews Gastroenterology & Hepatology, 2009
- IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated CancerCancer Cell, 2009
- Role of prostaglandin D 2 receptor DP as a suppressor of tumor hyperpermeability and angiogenesis in vivoProceedings of the National Academy of Sciences of the United States of America, 2008
- ATL‐1, an analogue of aspirin‐triggered lipoxin A4, is a potent inhibitor of several steps in angiogenesis induced by vascular endothelial growth factorBritish Journal of Pharmacology, 2008
- Regulation of cyclooxygenase-2 (COX-2) expression in human pancreatic carcinoma cells by the insulin-like growth factor-I receptor (IGF-IR) systemCancer Letters, 2007
- Lipoxin A4stable analogs reduce allergic airway responsesviamechanisms distinct from CysLT1 receptor antagonismThe FASEB Journal, 2007
- The EP4 receptor antagonist, L-161,982, blocks prostaglandin E2-induced signal transduction and cell proliferation in HCA-7 colon cancer cellsExperimental Cell Research, 2007
- Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitisProceedings of the National Academy of Sciences, 2006